Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Melphalan
Drug ID BADD_D01376
Description An alkylating nitrogen mustard that is used as an antineoplastic in the form of the levo isomer - melphalan, the racemic mixture - merphalan, and the dextro isomer - medphalan; toxic to bone marrow, but little vesicant action; potential carcinogen.
Indications and Usage For the palliative treatment of multiple myeloma and for the palliation of non-resectable epithelial carcinoma of the ovary. Has also been used alone or as part of various chemotherapeutic regimens as an adjunct to surgery in the treatment of breast cancer, alone or in combination regimens for palliative treatment of locally recurrent or unresectable in-transit metastatic melanoma of the extremities, as well as for the treatment of amyloidosis with prednisone.
Marketing Status Prescription; Discontinued
ATC Code L01AA03
DrugBank ID DB01042
KEGG ID D00369
MeSH ID D008558
PubChem ID 460612
TTD Drug ID D00FGO
NDC Product Code 68152-109; 71052-158; 52609-0001; 68554-0076; 50683-0385; 72893-001; 43744-361; 76055-0021; 72969-046
Synonyms Melphalan | L-PAM | Phenylalanine Mustard | Mustard, Phenylalanine | 4-(Bis(2-chloroethyl)amino)phenylalanine | Medphalan | Sarkolysin | Sarcolysine | Merphalan | Alkeran
Chemical Information
Molecular Formula C13H18Cl2N2O2
CAS Registry Number 148-82-3
SMILES C1=CC(=CC=C1CC(C(=O)O)N)N(CCCl)CCCl
Chemical Structure
ADRs Induced by Drug
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Acute leukaemia01.10.02.001; 16.01.02.001--Not Available
Acute myeloid leukaemia01.10.05.001; 16.01.05.0010.000139%Not Available
Acute promyelocytic leukaemia01.10.05.003; 16.01.05.0030.001066%Not Available
Agranulocytosis01.02.03.0010.000533%Not Available
Alanine aminotransferase increased13.03.01.0030.013321%
Alopecia23.02.02.001--
Amenorrhoea05.05.01.002; 21.01.02.001--
Anaemia01.03.02.001--
Anaphylactic reaction10.01.07.001; 24.06.03.006--
Anaphylactic shock10.01.07.002; 24.06.02.004--Not Available
Aplasia03.02.01.002; 08.03.04.0030.001332%Not Available
Arrhythmia02.03.02.001--Not Available
Arterial thrombosis24.01.01.002--Not Available
Aspartate aminotransferase increased13.03.01.0060.013321%
Asthenia08.01.01.001--Not Available
Atrial fibrillation02.03.03.0020.002398%
Bladder irritation20.02.02.020--Not Available
Bladder pain20.02.02.001--Not Available
Blood bilirubin increased13.03.01.0080.004263%
Blood creatine phosphokinase increased13.04.01.001--
Blood uric acid increased13.02.04.001--Not Available
Bone sarcoma15.09.03.001; 16.29.03.0010.000799%Not Available
Bronchospasm10.01.03.012; 22.03.01.004--
Cardiac arrest02.03.04.001--
Cataract06.06.01.0010.001332%
Chest pain02.02.02.011; 08.01.08.002; 22.02.08.003--Not Available
Compartment syndrome15.05.05.005; 24.04.05.0060.000533%Not Available
Confusional state17.02.03.005; 19.13.01.0010.001066%
Cough22.02.03.001--
Cystitis11.01.14.001; 20.03.02.002--
The 1th Page    1 2 3 4 5    Next   Last    Total 6 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene